CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.

Hassan, Saima; Buchanan, Marguerite; Jahan, Kaushar; Aguilar-Mahecha, Adriana; Gaboury, Louis; Muller, William J; Alsawafi, Yaqoob; Mourskaia, Anna A; Siegel, Peter M; Salvucci, Ombretta; Basik, Mark

Hassan, Saima; Buchanan, Marguerite; Jahan, Kaushar; Aguilar-Mahecha, Adriana; Gaboury, Louis; Muller, William J; Alsawafi, Yaqoob; Mourskaia, Anna A; Siegel, Peter M; Salvucci, Ombretta; Basik, Mark.

Affiliation

Hassan S; Department of Oncology, Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Canada.

Int J Cancer ; 129(1): 225-32, 2011 Jul 01.

Article in En | MEDLINE | ID: mdl-20830712

Subject(s)

Antineoplastic Agents/pharmacology; Cell Division/drug effects; Mammary Neoplasms, Experimental/pathology; Neoplasm Metastasis/prevention & control; Peptides/pharmacology; Receptors, CXCR4/antagonists & inhibitors; Taxoids/pharmacology; Vascular Endothelial Growth Factor A/antagonists & inhibitors; Animals; Blotting, Western; Disease Models, Animal; Docetaxel; Immunohistochemistry; Male; Mice; Mice, Transgenic

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptides / Cell Division / Receptors, CXCR4 / Taxoids / Vascular Endothelial Growth Factor A / Mammary Neoplasms, Experimental / Neoplasm Metastasis / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals Language: En Journal: Int J Cancer Year: 2011 Type: Article Affiliation country: Canada

Fulltext

XML

PubMed Links

Search on Google